Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar

Simple item page
dc.contributor.authorÇay H.F.
dc.contributor.authorMelikoğlu M.A.
dc.contributor.authorYurdakul F.G.
dc.contributor.authorBodur H.
dc.contributor.authorAtaman Ş.
dc.contributor.authorÇapkın E.
dc.contributor.authorGürer G.
dc.contributor.authorSezer İ.
dc.contributor.authorDuruöz M.T.
dc.contributor.authorRezvani A.
dc.contributor.authorYağcı İ.
dc.contributor.authorGöğüş F.
dc.contributor.authorKamanli A.
dc.contributor.authorÇevik R.
dc.contributor.authorAkgül Ö.
dc.date.accessioned2024-07-22T08:02:23Z
dc.date.available2024-07-22T08:02:23Z
dc.date.issued2023
dc.description.abstractObjectives: Considering that the comorbid situations during the management of Spondyloarthritis (SpA) have been underlined in several recommendations, the main objective of this study was to evaluate the comorbid conditions of Turkish patients with SpA. Patients and methods: This cross-sectional observational study was conducted with 1,242 SpA patients (844 males, 398 females; mean age: 43.9±11.0 years; range, 19 to 81 years) diagnosed according to the modified New York criteria for ankylosing spondylitis or the Assessment of SpondyloArthritis International Society (ASAS) criteria. The patient data were collected from the Biologic and targeted Synthetic antirheumatic drugs Registry (BioStar) between February 1, 2019, and December 29, 2020. Clinical and demographic data, including, age, sex, disease duration, body mass index (BMI), pain, patient’s global assessment, physician’s global assessment, Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, and Maastricht Enthesitis Score, were recorded. Comorbid conditions were recorded by filling out a questionnaire according to the clinical history or medical records. Charlson Comorbidity Index and Rheumatic Disease Comorbidity Index scores were calculated from the gathered comorbidity information. Results: Nine hundred thirteen patients had radiographic axial SpA, 153 had nonradiographic axial SpA, and 176 had peripheral SpA. The most common comorbidities were hypertension (HT) (n=167, 13.4%), diabetes mellitus (DM) (n=83, 6.7%), thyroid disorders (n=64, 5.6%), and depression (n=61, 4.9%). The comorbidities and the calculated comorbidity indices were significantly higher in females, in those with a BMI >25 kg/m2, and those over 60 years of age. No relationship was found between smoking and alcohol use and comorbidities. A significantly higher prevalence of HT and DM in peripheral SpA patients and a lower prevalence of thyroid disorders in radiographic axial SpA patients were observed. Conclusion: The most commonly reported comorbidities were HT, DM, thyroid disorders, and depression in SpA patients according to the BioStar database. The frequency of comorbidities and composite comorbidity scores were higher among females, older (>60 years) patients, and overweight (BMI >25 kg/m2) patients. © 2023 Turkish League Against Rheumatism. All rights reserved.
dc.identifier.DOI-ID10.46497/ArchRheumatol.2023.9793
dc.identifier.issn26186500
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11843
dc.language.isoEnglish
dc.publisherTurkish League Against Rheumatism (TLAR)
dc.rightsAll Open Access; Gold Open Access
dc.subjectacute heart infarction
dc.subjectadult
dc.subjectaged
dc.subjectalcohol consumption
dc.subjectAnkylosing Spondylitis Disease Activity Score
dc.subjectArticle
dc.subjectBath ankylosing spondylitis disease activity index
dc.subjectBath ankylosing spondylitis functional index
dc.subjectBiologic and targeted Synthetic antirheumatic drugs Registry
dc.subjectbody mass
dc.subjectbody weight
dc.subjectcardiovascular disease
dc.subjectcerebrovascular disease
dc.subjectCharlson Comorbidity Index
dc.subjectchronic lung disease
dc.subjectcomorbidity
dc.subjectcongestive heart failure
dc.subjectcross-sectional study
dc.subjectdepression
dc.subjectdiabetes mellitus
dc.subjectdiabetic complication
dc.subjectdisease assessment
dc.subjectdisease duration
dc.subjectdisease registry
dc.subjectenthesitis
dc.subjecterythrocyte sedimentation rate
dc.subjectfemale
dc.subjectgastrointestinal hemorrhage
dc.subjecthemiparesis
dc.subjecthuman
dc.subjecthypertension
dc.subjectkidney disease
dc.subjectKruskal Wallis test
dc.subjectMaastricht Ankylosing Spondylitis Enthesitis Score
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmalignant neoplasm
dc.subjectmulticenter study
dc.subjectmusculoskeletal disease assessment
dc.subjectnon-radiographic axial spondyloarthritis
dc.subjectobesity
dc.subjectobservational study
dc.subjectpain
dc.subjectpain assessment
dc.subjectpatient global assessment
dc.subjectpelvis radiography
dc.subjectpeptic ulcer
dc.subjectphysician
dc.subjectphysician global assessment
dc.subjectprevalence
dc.subjectquestionnaire
dc.subjectRheumatic Disease Comorbidity Index
dc.subjectsmoking
dc.subjectspondylarthritis
dc.subjectthyroid disease
dc.subjectTurk (people)
dc.titleReal-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar
dc.typeArticle

Files

Collections

Scopus Koleksiyonu